Table 3 Sensitivity analysis results
Dose escalation | Site-of-care | |||
|---|---|---|---|---|
Cost per remission, US$ | Increase from base case, US$ | Cost per remission, US$ | Increase from base case, US$ | |
Tofacitinib 10 mg PO BID | 205,240 | $0 | 205,240 | – |
Tofacitinib 5 mg PO BID | 249,417 | $0 | 249,417 | – |
Infliximab 5 mg/kg IV Q8W | 322,003 | 54,540 | 342,076 | 74,613 |
Vedolizumab 300 mg IV Q8W | 387,487 | 22,437 | 459,275 | 94,225 |
Golimumab 100 mg SC Q4W | 605,351 | 25,729 | 579,622 | – |
Adalimumab 40 mg SC Q2W | 820,100 | 69,900 | 750,200 | – |
Ustekinumab 90 mg SC Q8W | 999,329 | 211,331 | 787,998 | – |